Colchicine

Colchicine is used for treating and preventing pain associated with gouty arthritis.

Product dosage: 0.5mg
Package (num)	Per pill	Price	Buy
60	$0.95	$57.00 (0%)	🛒 Add to cart
90	$0.79	$85.50 $71.00 (17%)	🛒 Add to cart
120	$0.70	$114.00 $84.00 (26%)	🛒 Add to cart
180	$0.62	$171.00 $112.00 (35%)	🛒 Add to cart
270	$0.56	$256.50 $152.00 (41%)	🛒 Add to cart
360	$0.54 Best per pill	$342.00 $193.00 (44%)	🛒 Add to cart
Synonyms Artrichine Cochic Colchicina Colchicindon Colchicinum Colchicum Colchidrint Colchimedio Colchiquim Colchis Colchisol Colchysat Colcitrat Colcout Colcrys Colgout Conicine Cp-colchi Dochicin Goutichine Goutnil Kolsin Lengout Sixol Tolchicine Xuric

Colchicine is a time-tested alkaloid medication derived from the Colchicum autumnale plant, historically known as autumn crocus or meadow saffron. It represents a cornerstone in the management of acute gout flares and familial Mediterranean fever (FMF). Its primary mechanism of action involves binding to tubulin, inhibiting microtubule polymerization, and thereby disrupting the inflammatory cascade mediated by neutrophil migration and phagocytosis. This results in a potent anti-inflammatory effect specifically targeted at crystal-induced arthropathies. It is not a general analgesic or urate-lowering therapy but is indispensable for aborting acute gouty attacks and for FMF prophylaxis.

Features

• Derived from the Colchicum autumnale plant.
• Specific inhibitor of microtubule polymerization.
• Disrupts neutrophil motility, adhesion, and phagocytosis.
• Available in oral tablet formulations (typically 0.6 mg).
• Indicated for acute gout flares and prophylaxis, and familial Mediterranean fever.
• Not considered a first-line analgesic for non-crystal-induced pain.

Benefits

• Rapid Abortion of Gout Flares: Effectively reduces the pain, swelling, and erythema associated with acute gouty arthritis when administered early in an attack.
• Prophylactic Efficacy: Low-dose regimens can significantly reduce the frequency and severity of recurrent gout flares.
• FMF Management: Provides critical prophylaxis against attacks of familial Mediterranean fever and can prevent the development of systemic amyloidosis, a serious complication of the disease.
• Targeted Mechanism: Its action is specific to the inflammatory pathways involved in crystal deposition diseases, offering a targeted rather than a generalized immunosuppressive effect.
• Well-Established Safety Profile: When used at appropriate dosages and with careful patient selection, its safety and efficacy are well-documented through decades of clinical use.

Common use

Colchicine is predominantly prescribed for two main conditions. Its primary use is in the treatment and prophylaxis of acute gout flares. For an acute attack, it is most effective when administered within the first 36 hours of symptom onset. It is also used for long-term prophylaxis to prevent recurrent attacks, particularly during the initial months of therapy with a urate-lowering agent like allopurinol or febuxostat, to counteract the increased risk of flares associated with fluctuating serum uric acid levels. Its second major indication is for the treatment and prophylaxis of familial Mediterranean fever (FMF), an autoinflammatory genetic disorder. Off-label uses may include the management of other autoinflammatory conditions such as Behçet’s disease, pericarditis, and pseudogout (calcium pyrophosphate deposition disease), though evidence and dosing regimens can vary.

Dosage and direction

Dosing is highly indication-specific and must be strictly adhered to due to a narrow therapeutic index.

• Acute Gout Flare (Treatment): The recommended regimen is 1.2 mg (two 0.6 mg tablets) at the first sign of a flare, followed by one 0.6 mg tablet one hour later. This is a full course of 1.8 mg over one hour. This course should not be repeated for at least three days.
• Gout Prophylaxis: The typical prophylactic dose is 0.6 mg once or twice daily. The maximum dose for prophylaxis is usually 1.2 mg per day. The duration of prophylaxis is typically 6 months or as long as the patient is starting or titrating a urate-lowering drug.
• Familial Mediterranean Fever (FMF): Dosing is weight- and severity-dependent. For adults, the daily dose typically ranges from 1.2 mg to 2.4 mg, administered once daily or in divided doses. Pediatric dosing is based on body weight and must be carefully calculated by a physician.
• Administration: Tablets should be taken with a full glass of water, with or without food. However, if gastrointestinal upset occurs, taking it with food may help alleviate symptoms.

Always follow the specific dosage instructions provided by the prescribing physician, as individual patient factors (e.g., renal or hepatic impairment) will significantly alter the safe dosing regimen.

Precautions

Extreme caution is required when prescribing and taking colchicine due to its narrow therapeutic window.

• Renal Impairment: Patients with impaired kidney function are at a substantially increased risk of severe and potentially fatal toxicity. Dosage must be aggressively reduced or the drug avoided entirely in patients with severe renal impairment. Concomitant use with drugs that inhibit P-glycoprotein (P-gp) or CYP3A4 is particularly dangerous in this population.
• Hepatic Impairment: Patients with severe liver disease should use colchicine with caution, as metabolism and clearance may be affected, leading to increased drug levels.
• Elderly Patients: Advanced age is often associated with reduced renal function and increased susceptibility to side effects, particularly myelosuppression and myotoxicity. Lower doses and close monitoring are mandatory.
• Blood Monitoring: Patients on long-term therapy, especially those with borderline renal function or on interacting drugs, should undergo periodic monitoring of complete blood counts (CBC) and creatine phosphokinase (CPK) levels to check for bone marrow suppression and muscle damage.
• Pregnancy and Lactation: Use during pregnancy may be considered for treating FMF but requires a thorough risk-benefit assessment by a specialist. It is excreted in breast milk; caution is advised during breastfeeding.

Contraindications

Colchicine is contraindicated in patients with:

• Known hypersensitivity to colchicine or any ingredient in the formulation.
• Severe renal impairment (e.g., estimated glomerular filtration rate (eGFR) <30 mL/min) in the presence of concomitant therapy with a strong P-gp or CYP3A4 inhibitor.
• Severe hepatic impairment.
• Concomitant administration of potent P-glycoprotein (P-gp) or strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, cyclosporine, ritonavir) in patients with any degree of renal or hepatic impairment. This combination dramatically increases the risk of life-threatening toxicity.

Possible side effect

Side effects are often dose-dependent and primarily involve the gastrointestinal system.

• Very Common (>10%): Diarrhea, nausea, vomiting, abdominal pain.
• Common (1-10%): Pharyngolaryngeal pain.
• Uncommon (0.1-1%): Myotoxicity (muscle pain, weakness, elevated CPK), neuropathy (tingling, numbness), leukopenia, neutropenia, thrombocytopenia, alopecia.
• Rare (<0.1%): Pancytopenia, bone marrow suppression, aplastic anemia, rhabdomyolysis (especially with concomitant statin use), organ failure in overdose.

Gastrointestinal symptoms often appear as the first sign of toxicity. Their occurrence, especially diarrhea, during treatment for an acute gout flare should prompt discontinuation of the drug.

Drug interaction

Colchicine has numerous serious and potentially fatal drug interactions, primarily mediated through the P-glycoprotein (P-gp) transporter and the CYP3A4 enzyme system.

• Strong CYP3A4 Inhibitors: Clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nefazodone. Concomitant use is contraindicated in patients with renal or hepatic impairment and requires extreme caution or contraindication in others.
• P-gp Inhibitors: Cyclosporine, ranolazine. Significantly increase colchicine plasma levels. Use is generally contraindicated or requires drastic dose reduction.
• Moderate CYP3A4 or P-gp Inhibitors: Verapamil, diltiazem, amiodarone, quinidine, fibrates (e.g., fenofibrate, gemfibrozil). Concomitant use requires a dose reduction of colchicine and close monitoring.
• Statins (HMG-CoA Reductase Inhibitors): Atorvastatin, simvastatin, rosuvastatin. Increase the risk of myopathy and rhabdomyolysis. Patients should be monitored for muscle pain or weakness.
• Macrolide Antibiotics (other than clarithromycin): Erythromycin, azithromycin. Azithromycin is a weaker inhibitor, but caution is still advised.

A comprehensive medication review is essential before initiating colchicine therapy.

Missed dose

• If a dose is missed for prophylaxis (e.g., gout or FMF), it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not double the dose to make up for the missed one.
• In the context of treating an acute gout flare, the dosing is a specific course. If the regimen is interrupted, consult a physician for guidance. Do not simply continue the course later.

Overdose

Colchicine overdose is extremely dangerous and can be fatal. Toxicity unfolds in three phases:

1. Gastrointestinal Phase (2-24 hours): Severe nausea, vomiting, diarrhea, and abdominal pain leading to fluid loss and electrolyte imbalances.
2. Multi-Organ Failure Phase (24 hours to 7 days): This phase involves life-threatening complications including bone marrow suppression (pancytopenia), disseminated intravascular coagulation (DIC), rhabdomyolysis, renal failure, hepatic injury, arrhythmias, and progressive multi-organ failure. Respiratory distress and neurological decline may occur.
3. Recovery Phase (weeks): If the patient survives, recovery of organ function occurs but is often prolonged, with alopecia being a common late sign.

There is no specific antidote. Management is entirely supportive and must be conducted in an intensive care unit (ICU). It includes aggressive gastrointestinal decontamination (if early), fluid and electrolyte replacement, pressor support, and treatment of complications such as infection secondary to neutropenia. Early consultation with a poison control center is critical.

Storage

• Store at room temperature (20°C to 25°C or 68°F to 77°F).
• Keep the container tightly closed.
• Protect from light and moisture.
• Keep out of reach of children and pets.
• Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and is not a substitute for the professional judgment of a qualified healthcare provider in diagnosing and treating patients. The content does not provide medical advice or recommend specific products. Dosage, indications, and safety information can change. Always consult with a physician or other qualified health provider with any questions you may have regarding a medical condition, symptom, or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

• “As a rheumatologist with over 20 years of practice, colchicine remains an invaluable tool for managing acute crystal arthropathies. Its efficacy is undeniable when used correctly, but its narrow therapeutic index demands immense respect and careful patient education.” – Dr. A. Smith, MD
• “For my patients with FMF, colchicine is a life-changing medication. It prevents debilitating attacks and the devastating complication of amyloidosis. Monitoring is key, but the benefits overwhelmingly outweigh the risks.” – Dr. L. Chen, MD
• “Patient perspective: It works wonders to stop a gout attack in its tracks if I take it at the very first twinge of pain. The stomach upset can be significant, but it’s a trade-off I’m willing to make to avoid days of agony.” – Verified Patient
• “The number of serious drug interactions cannot be overstated. In my clinical pharmacy practice, intercepting a dangerous interaction between colchicine and a newly prescribed antibiotic is a critical intervention that prevents potential tragedy.” – Clinical Pharmacist, BCOP